Targeted therapy: RAS mimetic revealed
Nature Reviews Cancer 16, 342 (2016).
doi:10.1038/nrc.2016.59
Author: Alexandra Flemming
The small-molecule inhibitor rigosertib acts as a RAS mimetic — by disrupting the association of RAS with RAF and other effector proteins, it inactivates RAS downstream signalling.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Alexandra Flemming Tags: Research Highlight Source Type: research
More News: Cancer | Cancer & Oncology